| Document |
Document Title |
|
WO/2021/160799A1 |
The current invention is based, at least in part, on the finding that the transverse nuclear magnetic spin relaxation time T2 and the transverse nuclear magnetic spin relaxation rate R2, respectively, of protons of water molecules in an ...
|
|
WO/2021/160787A1 |
The present invention relates to a separation method comprising: i) providing an aqueous solution comprising a target compound; ii) applying a separation step to the aqueous solution, thereby providing a plurality of fractions of the aqu...
|
|
WO/2021/156404A2 |
The invention provides methods for treating infections, disorders or diseases caused by a human papillomavirus other than HPV-16 by determining the HPV type of the patient, providing a synthetic-long-peptide based therapeutic vaccine for...
|
|
WO/2021/158146A1 |
The aim of the invention is to create a recombinant immunologically active GDF11 protein that is easily purified and has sufficient immunogenicity with respect to the growth differentiation factor 11 protein, which can be used to increas...
|
|
WO/2021/157421A1 |
Provided is a method for producing a target protein using a plant as an expression host. The target protein is produced by adding an HA tag to express the target protein in a plant, and extracting the target protein in the presence of an...
|
|
WO/2021/158444A2 |
ABSTRACT OF THE DISCLOSURE A Solid Phase Peptide Synthesis (SPPS) device and method of using the same for manufacturing peptides is taught herein. The system comprises at least two reactors, each reactor including a quantity of SPPS resi...
|
|
WO/2021/156331A2 |
The invention relates to use of ionic polymers (IP) consisting of anions and a polymeric backbone containing cations, in hydrolyzing proteins and protein-containing feedstock to produce protein hydrolysates.
|
|
WO/2021/152584A1 |
A method of precipitating nanostructures out of a mixture of cellular components is disclosed. The nanostructures have an outer surface comprising phospholipids. The method comprises contacting the mixture with an oligo-amine having a su...
|
|
WO/2021/152622A1 |
Improved process for the preparation of Liraglutide having the structural formula (I). His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-
Gly-Gln-Ala-Ala-Lys(Glu-Palmitoyl)-Glu-Phe-lle-Ala-Trp-Leu-V
al-Arg-Gly-Arg-Gly-OH Formul...
|
|
WO/2021/154908A1 |
Provided herein are methods of separating host cell lipases from an anti-LAG3 antibody or antigen binding fragment in chromatographic processes and methods of improving polysorbate-80 stability in an anti-LAG3 antibody formulation by sep...
|
|
WO/2021/150794A1 |
Described herein are protein compositions comprising low molecular weight proteins, water insoluble, and non- hygroscopic properties, methods of treating diseases or conditions using such compositions, and methods of inhibiting angiotens...
|
|
WO/2021/147869A1 |
A method for preparing a Liraglutide product, in which Fmoc modification is performed on a Boc-modified Liraglutide backbone chain and sidechain addition of Liraglutide is implemented using Fmoc modification. A Fmoc- and Boc-modified Lir...
|
|
WO/2021/147857A1 |
Provided is a method for improving impurities removal in the protein purification by affinity chromatography, comprising 1) loading a protein sample onto an affinity chromatography column, 2) washing the column with a wash buffer solutio...
|
|
WO/2021/150996A1 |
The disclosure provides methods of purifying native and recombinant biomolecules, e.g., proteins, from mammalian cells using purification protocols incorporating harvest recovery operations involving decanter centrifugation of at least o...
|
|
WO/2021/150614A1 |
The present disclosure relates to compounds and methods for selective C-terminal functionalization of peptides. In certain embodiments, the compounds have improved water-solubility, and are suitable for use in connection with peptide seq...
|
|
WO/2021/150558A1 |
The disclosure relates to methods of analyzing a post-translationally modified protein of interest using electrophoresis, the methods comprising deglycosylating the protein of interest after labeling.
|
|
WO/2021/149814A1 |
The present invention provides a catalyst containing a Brønsted acid as a novel means capable of producing an amide compound by highly stereoselectively and/or highly efficiently causing an amidation reaction in a variety of substrates ...
|
|
WO/2021/147361A1 |
Provided are a zinc ion complex peptide, and a complex and the use thereof. The amino acid composition sequence of the zinc ion complex peptide is Lys-Tyr-Lys-Arg-Gln-Arg-Trp (KYKRQRW). The complex peptide is derived from soybeans or pea...
|
|
WO/2021/146630A1 |
The present application provides a method for characterizing and/or determining viral clearance capacity of hydrophobic interaction chromatography (HIC) including experimental design for multivariate analysis of viral clearance of HIC. T...
|
|
WO/2021/143073A1 |
A preparation method for semaglutide. The method comprises: producing a semaglutide resin by means of a solid-phase synthesis, producing crude semaglutide by cleavage and deprotection, producing refined semaglutide by purification and fr...
|
|
WO/2021/144422A1 |
The invention relates to a method of reducing the amount of non-aggregate product-related impurities (NAPRIs) in a buffered solution of monoclonal antibodies (mAbs), involving the use of a synthetic depth filter. The invention may be of ...
|
|
WO/2021/143572A1 |
Disclosed is a preparation method for PEGylated biomolecules having controllable binding sites, comprising the following steps: (1) PEGylating biomolecules; (2) binding a barrier to at least one binding site in the PEGylated biomolecules...
|
|
WO/2021/143159A1 |
Provided is a method for synthesizing liraglutide, comprising obtaining liraglutide resin by means of solid-phase synthesis, carrying out cleavage and deprotection to obtain a crude peptide of liraglutide, and carrying out purification t...
|
|
WO/2021/142880A1 |
Disclosed is a method for preparing a clam active peptide. The method comprises: washing fresh clam meat with water, and adding water and homogenizing the mixture with colloids to prepare a clam pulp; adding water and a compound protease...
|
|
WO/2021/142710A1 |
Disclosed in the present invention are a Ganoderma lucidum mycelium antihypertensive peptide and a preparation method therefor, belonging to the technical fields of polypeptide biotechnologies and antihypertensive drugs. The antihyperten...
|
|
WO/2021/143573A1 |
A preparation method for a disubstituted PEGylated interleukin 2, comprising the steps of: (1) PEGylating IL-2 to obtain a PEGylated interleukin crude product; (2) performing gel chromatography filtration to remove free interleukin 2 fro...
|
|
WO/2021/139720A1 |
A purification method for adalimumab, a stable adalimumab composition obtained by the purification method, and pharmaceutical use of the composition.
|
|
WO/2021/142133A1 |
Embodiments of the present invention implement DNA assembly using a microfluidics channel having an integrated solid phase column. The presence of a solid phase enables purification of nucleic acid products by selective capture and eluti...
|
|
WO/2021/135765A1 |
Provided is a salt conversion method for a GLP-1 analogue, comprising the following steps: 1) sample preparation: preparing a purified fraction of the GLP-1 analogue; 2) sample dilution: diluting the purified fraction by using deionized ...
|
|
WO/2021/135437A1 |
Provided are a polypeptide probe for specifically detecting pathological collagens, and a preparation method therefor and the use thereof. The polypeptide probe contains a polypeptide sequence (Gly-Hyp-Pro) n and a signal molecule modifi...
|
|
WO/2021/134180A1 |
The present invention relates to the field of blood products, and disclosed is a method for cryopreserving a blood coagulation factor VIII (FVIII) intermediate product. The blood coagulation FVIII intermediate product is taken from an FV...
|
|
WO/2021/138288A1 |
Provided herein is a method of delivering a biological material, including a genome-editing agent, to the interior of a plant cell wherein the method includes contacting the plant cell with a complex comprising the biological material an...
|
|
WO/2021/136521A1 |
Disclosed is a polypeptide. The polypeptide has a modification at the N-terminus compared with polypeptides having the following amino acid sequences: (1) a polypeptide having the amino acid sequences represented by SEQ ID NOs: 1 to 6; o...
|
|
WO/2021/137844A1 |
An apparatus for preparing nucleic acid sequences using an enzyme, including a reactor, a plurality of nucleotide material bottles, a deblocking material bottle, and a liquid delivering device. The reactor includes a reaction substrate h...
|
|
WO/2021/135732A1 |
Provided are a polymyxin B component or a salt thereof, and a preparation method therefor and the use thereof. The polymyxin B component comprises 1-position α,γ-diaminobutyric acid, 2-position threonine, 3-position α,γ-diaminobutyri...
|
|
WO/2021/136121A1 |
Disclosed is a method for preparing a cysteic acid-containing polypeptide. The method comprises: synthesizing a peptide resin containing S-tert-butylmercapto-protected cysteine by means of taking S-tert-butylmercapto-protected cysteine a...
|
|
WO/2021/129579A1 |
A heme derivative and a preparation method and a use thereof. Specifically, provided are a heme derivative as represented by formula I, or pharmaceutically acceptable salts, enantiomers, diastereoisomers, or raceme thereof. The heme deri...
|
|
WO/2021/129016A1 |
Disclosed is a method for desalting polypeptides, the method comprising loading a polypeptide sample onto a preparative column, rinsing the column with mobile phases A1 and B, then rinsing the column with mobile phases A2 and B, and fina...
|
|
WO/2021/130645A1 |
The present invention relates to an improved process for the preparation of Liraglutide. The present invention further related an improved process for the preparation of substantially pure material having a purity of greater than or equa...
|
|
WO/2021/133033A1 |
The present invention provides a method for producing a PNA oligomer. More specifically, the method comprises a step for reacting a PNA block and a PNA block in a solution to produce a PNA oligomer, and thus a PNA oligomer of interest ca...
|
|
WO/2021/132957A1 |
The present invention relates to a method for purifying follicle stimulating hormone with high yield and high purity.
|
|
WO/2021/132336A1 |
According to the present invention, a peptide is efficiently produced by reacting a carboxyl group of an amino acid wherein an amino group is protected or an intermediate peptide with an alkali metal salt or an alkaline earth metal salt ...
|
|
WO/2021/130383A1 |
The invention relates to a method for the production of a bispecific CD30xCD16A antibody construct comprising a first binding domain for FcyRIIla comprising the steps chromatographically capturing the antibody construct from a solution; ...
|
|
WO/2021/129308A1 |
Disclosed is a method for purifying a GLP-1 analog, the method comprising the following steps: 1) purifying a GLP-1 analog by means of anion exchange; 2) purifying the purified substance obtained in 1) by means of reversed-phase chromato...
|
|
WO/2021/130717A1 |
The present invention provides a method for purifying an Fc-containing biologically active peptide mixture by using an affinity column comprising an affinity matrix that contains a protein A ligand, the mixture comprising a first Fc-cont...
|
|
WO/2021/133032A1 |
The present invention provides a modified gamma-carbon skeleton compound and a method for preparing same. The modified gamma-carbon skeleton compound of the present invention can produce a peptide nucleic acid monomer with high yield and...
|
|
WO/2021/132545A1 |
The present inventors have found that a C-terminal activator can be removed by mixing a solution containing the C-terminal activator remaining after a condensation reaction, with a tertiary amine and water or an aqueous solution, in the ...
|
|
WO/2021/132958A1 |
The present invention pertains to a method for purifying a follicle-stimulating hormone with high yield and high purity, the method comprising an immunoaffinity chromatography (IAC) step.
|
|
WO/2021/122744A1 |
The present invention relates to the chemical synthesis of amanin and its derivatives. The present invention also relates to intermediate products of the amanin synthesis.
|
|
WO/2021/120900A1 |
Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.
|
